Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.
COVID-19
E484k mutation
Neutralizing antibodies
SARS-CoV-2 lineages
Spike protein
Variant of Interest
Journal
Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979
Informations de publication
Date de publication:
15 01 2022
15 01 2022
Historique:
received:
27
09
2021
revised:
20
10
2021
accepted:
10
11
2021
pubmed:
16
11
2021
medline:
2
2
2022
entrez:
15
11
2021
Statut:
ppublish
Résumé
The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in different variants around the world and has been widely associated with immune escape from neutralizing antibodies generated during previous infection or vaccination. In this work, the B.1 + L249S+E484K lineage was isolated along with A.1, B.1.420, and B.1.111 SARS-CoV-2 lineages without the E484K mutation and the neutralizing titer of convalescent sera was compared using microneutralization assays. While no significant differences in the neutralizing antibody titers were found between A.1 and B.lineages without the E484K mutation, the neutralizing titers against B.1 + L249S+E484K were 1.5, 1.9, 2.1, and 1.3-fold lower than against A.1, B.1.420, B.1.111-I, and B.1.111-II, respectively. However, molecular epidemiological data indicate that there is no increase in the transmissibility rate associated with this new lineage. This study supports the capability of new variants with the E484K mutation to be resistant to neutralization by humoral immunity, and therefore the need to intensify surveillance programs to determine if these lineages represent a risk for public health.
Identifiants
pubmed: 34780883
pii: S0168-1702(21)00336-1
doi: 10.1016/j.virusres.2021.198629
pmc: PMC8585963
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
198629Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Vaccines (Basel). 2021 Apr 15;9(4):
pubmed: 33920999
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
J Mol Biol. 2021 Jul 23;433(15):167058
pubmed: 34023401
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
Clin Microbiol Infect. 2021 Aug;27(8):1109-1117
pubmed: 34015535
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Infect Genet Evol. 2021 Sep;93:104941
pubmed: 34044192
Signal Transduct Target Ther. 2021 Feb 26;6(1):95
pubmed: 33637679
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Infect Genet Evol. 2021 Nov;95:105038
pubmed: 34403832
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):82-87
pubmed: 32859866
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
Emerg Infect Dis. 2020 Dec;26(12):2854-2862
pubmed: 33219646
Nature. 2021 Sep;597(7878):703-708
pubmed: 34428777
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Front Microbiol. 2020 Sep 04;11:2020
pubmed: 33013745
Lancet Microbe. 2021 Jul;2(7):e283-e284
pubmed: 33846703
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Methods Mol Biol. 2020;2099:107-116
pubmed: 31883091
Front Med (Lausanne). 2021 Jun 28;8:697605
pubmed: 34262921
Viruses. 2021 Apr 21;13(5):
pubmed: 33919314
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
PLoS One. 2021 Mar 10;16(3):e0248348
pubmed: 33690649
Brief Bioinform. 2019 Jul 19;20(4):1160-1166
pubmed: 28968734
Infect Genet Evol. 2020 Nov;85:104557
pubmed: 32950697